MedTrace Logo

Proteomics of Papillary Thyroid Carcinoma

NCT02814032 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2023-07-20

No results posted yet for this study

Summary

Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Conditions

  • Papillary Thyroid Carcinoma

Sponsors & Collaborators

  • The Affiliated Hospital of Inner Mongolia Medical University

    lead OTHER

Principal Investigators

  • Shan Jin, PhD · The Affiliated Hospital of Inner Mongolia Medical University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02814032 on ClinicalTrials.gov